{
    "clinical_study": {
        "@rank": "16765", 
        "arm_group": [
            {
                "arm_group_label": "T-817MA-H", 
                "arm_group_type": "Experimental", 
                "description": "448 mg T-817MA once daily"
            }, 
            {
                "arm_group_label": "T-817MA-L", 
                "arm_group_type": "Experimental", 
                "description": "224 mg T-817MA once daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and\n      ADCS-CGIC.\n\n      The secondary objectives are:\n\n        -  To evaluate the safety and tolerability of T-817MA measured by clinical safety\n           laboratories, physical examinations, ECGs and solicitation of adverse events.\n\n        -  To evaluate the efficacy of T-817MA as measured by ADCS-ADL, FAQ, Neuropsychiatric\n           Inventory (NPI) and Mini-mental State Examination (MMSE)."
        }, 
        "brief_title": "Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female (post-menopausal or surgically sterile)\n\n          -  Patients with Mild to moderate Alzheimer's disease who are receiving donepezil.\n             Memantine is allowed only when prescribed in combination with donepezil.\n\n          -  Age 55 to 85 inclusive\n\n          -  Patients must be living in the community\n\n          -  Patients must have an eligible informant or study partner (caregiver)\n\n          -  Patients and eligible informant or study partner (caregiver) must be able to read and\n             understand English.\n\n          -  Informed consent obtained from both the patient and the caregiver\n\n        Exclusion Criteria:\n\n          -  Patients with clinically significant cardiac, hepatic or renal impairment\n\n          -  Patient have a dementia not of the Alzheimer's type etc (According to the protocol)\n\n          -  Patients who are taking any drug other than donepezil for Alzheimer's disease,\n             including rivastigmine (Exelon\u00ae), galantamine (Razadyne\u00ae)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079909", 
            "org_study_id": "T817MAUS202"
        }, 
        "intervention": {
            "arm_group_label": [
                "T-817MA-H", 
                "T-817MA-L"
            ], 
            "description": "224 mg or 448 mg T-817 MA once daily", 
            "intervention_name": "T-817MA", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Alzheimer's Disease", 
            "Alzheimer's"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "La Jolla", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "UCSD Comprehensive Alzheimer's Program"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease", 
        "overall_contact": {
            "email": "gfmatthews@mail.ucsd.edu", 
            "last_name": "Genny Matthews", 
            "phone": "(858) 246-1318"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC.", 
            "safety_issue": "No", 
            "time_frame": "Time Frame 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079909"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the safety and tolerability of T-817MA measured by clinical safety laboratories, physical examinations, ECGs and solicitation of adverse events.", 
                "measure": "Clinical Safety", 
                "safety_issue": "Yes", 
                "time_frame": "56 weeks"
            }, 
            {
                "description": "To evaluate the efficacy of T-817MA as measured by ADCS-ADL, FAQ, Neuropsychiatric Inventory (NPI) and Mini-mental State Examination (MMSE).", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "56 weeks"
            }
        ], 
        "source": "Toyama Chemical Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Alzheimer's Disease Cooperative Study (ADCS)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Toyama Chemical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}